Syncom Formulations (India) Limited (BOM:524470)
14.33
-0.15 (-1.04%)
At close: Jun 16, 2026
BOM:524470 Revenue
In the fiscal year ending March 31, 2026, Syncom Formulations (India) had annual revenue of 4.89B INR with 5.20% growth. Syncom Formulations (India) had revenue of 1.35B in the quarter ending March 31, 2026, a decrease of -9.04%.
Revenue
4.89B
Revenue Growth
+5.20%
P/S Ratio
2.75
Revenue / Employee
6.57M
Employees
744
Market Cap
13.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 4.89B | 241.59M | 5.20% |
| Mar 31, 2025 | 4.65B | 2.02B | 76.55% |
| Mar 31, 2024 | 2.63B | 391.33M | 17.45% |
| Mar 31, 2023 | 2.24B | 45.91M | 2.09% |
| Mar 31, 2022 | 2.20B | -251.42M | -10.27% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hikal | 17.13B |
| TTK Healthcare | 8.57B |
| Lincoln Pharmaceuticals | 7.04B |
| Sudarshan Pharma Industries | 7.03B |
| Kopran | 6.81B |
| Wanbury | 6.50B |
| Fredun Pharmaceuticals | 6.35B |
| Fermenta Biotech | 5.25B |